neuroscience

Cognition Therapeutics’ Founder/CSO to Provide Update on Elayta™ Clinical Progress at ADDF Alzheimer’s Drug Discovery Conference

PITTSBURGH, September 10, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the company’s co-founder and chief science officer, Susan Catalano, Ph.D. will present an update on the Company’s lead candidate, Elayta™, at the 20th …

Cognition Therapeutics’ Founder/CSO to Provide Update on Elayta™ Clinical Progress at ADDF Alzheimer’s Drug Discovery Conference Read More »

Cognition Therapeutics to Sponsor Third International Symposium on Sigma-2 Receptors: Role in Health and Disease during the Society for Neuroscience Annual Meeting

PITTSBURGH, Oct. 24, 2018 – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced its sponsorship of the Third International Symposium on Sigma-2 Receptors: Role in Health and Disease. The Symposium will be held in San Diego, California on November 3, 2018 beginning …

Cognition Therapeutics to Sponsor Third International Symposium on Sigma-2 Receptors: Role in Health and Disease during the Society for Neuroscience Annual Meeting Read More »

Scroll to Top